AGL20 Apr 2018 10:31
Although AGL has started on breast, I do not know any reason why the technique of cell separation based on physical characteristics, size, deformability, etc should not also apply to all solid tumours, including lymphoma, where the present approach is by needle biopsy under x ray control, or an open procedure.
Work is presently proceeding on patients with stage 3/4 malignancies, with near 100% CTC recovery rates. it will be very interesting to discover at what stage in a malignancy can be picked up using Parsortix. Stage 1?, stage 2?, who knows?.
For eg,. we think of prostate cancer being intracapsular, or extra capsular ( ie metastatising), but localised tumours must have a blood supply, and it follows that tumour cells may possibly be found in peripheral blood, before there is evidence of extracapsular spread. If shown to be consistent, this would save on the need to have a prostatic needle biopsy via the arse, which cannot be very pleasant.
It seems that the possibilities with this kit are enormous.
I hope Parsortix is patented up to the hilt.